Fol. Biol. 2017, 63, 146-154

https://doi.org/10.14712/fb2017063040146

Expression of c-MET Protein in Various Subtypes of Hepatocellular Adenoma Compared to Hepatocellular Carcinoma and Non-Neoplastic Liver in Human Tissue

Grzegorz Szparecki, T. Ilczuk, N. Gabzdyl, E. Stocka-Łabno, B. Górnicka

Department of Pathology, Medical University of Warsaw, Poland

Received August 2017
Accepted October 2017

References

1. An, S. L., Wang, L. M., Rong, W. Q., Wu, F., Sun, W., Yu, W. B., Feng, L., Liu, F. Q., Tian, F., Wu, J. X. (2015) Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers. Chin. J. Cancer 34, 217-224. <https://doi.org/10.1186/s40880-015-0014-x>
2. Armaghany, T., Wilson, J. D., Chu, Q., Mills, G. (2012) Genetic alterations in colorectal cancer. Gastrointest. Cancer Res. 5, 19-27.
3. Bertino, G., Ardiri, A., Malaguarnera, M., Malaguarnera, G., Bertino, N., Calvagno, G. S. (2012) Hepatocellualar carcinoma serum markers. Semin. Oncol. 39, 410-433. <https://doi.org/10.1053/j.seminoncol.2012.05.001>
4. Bioulac-Sage, P., Balabaud, C., Bedossa, P., Scoazec, J. Y., Chiche, L., Dhillon, A. P., Ferrell, L., Paradis, V., Roskams, T., Vilgrain, V., Wanless, I. R., Zucman-Rossi, J., Laennec, Elves, G. (2007) Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J. Hepatol. 46, 521-527. <https://doi.org/10.1016/j.jhep.2006.12.007>
5. Cavalieri, E., Frenkel, K., Liehr, J. G., Rogan, E., Roy, D. (2000) Estrogens as endogenous genotoxic agents – DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 27, 75-93. <https://doi.org/10.1093/oxfordjournals.jncimonographs.a024247>
6. Chan, E., Alkhasawneh, A., Duckworth, L. V., Aijaz, T., Toro, T. Z., Lu, X., Hughes, S. J., Collinsworth, A., George, T. J., Jr. (2016) EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. J. Gastrointest. Oncol. 7, 838-847. <https://doi.org/10.21037/jgo.2016.06.09>
7. Chen, Z., He, X., Jia, M., Liu, Y., Qu, D., Wu, D., Wu, P., Ni, C., Zhang, Z., Ye, J., Xu, J., Huang, J. (2013) β-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis. PLoS One. 8, e63854. <https://doi.org/10.1371/journal.pone.0063854>
8. Chu, J. S., Ge, F. J., Zhang, B., Wang, Y., Silvestris, N., Liu, L. J., Zhao, C. H., Lin, L., Brunetti, A. E., Fu, Y. L., Wang, J., Paradiso, A., Xu, J. M. (2013) Expression and prognostic value of VEGFR-2, PDGFR-β and c-Met in advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 32, 16. <https://doi.org/10.1186/1756-9966-32-16>
9. Edmondson, H. A., Henderson, B., Benton, B. (1976) Livercell adenomas associated with use of oral contraceptives. N. Engl. J. Med. 294, 470-472. <https://doi.org/10.1056/NEJM197602262940904>
10. Farges, O., Ferreira, N., Dokmak, S., Belghiti, J., Bedossa, P., Paradis, V. (2011) Changing trends in malignant transformation of hepatocellular adenoma. Gut 60, 85-89. <https://doi.org/10.1136/gut.2010.222109>
11. Gayyed, M. F., Abd El-Maqsoud, N. M., El-Hameed El-Heeny, A. A., Mohammed, M. F. (2015) c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases. J. Gastrointest. Oncol. 6, 618-627.
12. Giordano, S., Columbano, A. (2014) Met as a therapeutic target in HCC: facts and hopes. J. Hepatol. 60, 442-452. <https://doi.org/10.1016/j.jhep.2013.09.009>
13. Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., Clement, B., Balabaud, C., Chevet, E., Laurent, A., Couchy, G., Letouze, E., Calvo, F., Zucman- Rossi, J. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694-698. <https://doi.org/10.1038/ng.2256>
14. Katabathina, V. S., Menias, C. O., Shanbhogue, A. K., Jagirdar, J., Paspulati, R. M., Prasad, S. R. (2011) Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics 31, 1529-1543. <https://doi.org/10.1148/rg.316115527>
15. Kim, D. H., Kim, S. U., Nam, D. H., Choi, Y. J., Park, S. M., Lee, C. K., Kim do, Y. (2009) A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male. Korean J. Intern. Med. 24, 147-152. <https://doi.org/10.3904/kjim.2009.24.2.147>
16. Larson, K. A., Weber, S. M., Fong, Y., Blumgart, L. H. (2002) Malignant transformation of hepatic adenoma with recurrence after resection. HPB (Oxford) 4, 139-143. <https://doi.org/10.1080/136518202760388055>
17. Lee, S. J., Lee, J., Sohn, I., Mao, M., Kai, W., Park, C. K., Lim, H. Y. (2013) A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 33, 5179-5186.
18. Llovet, J. M., Burroughs, A., Bruix, J. (2003) Hepatocellular carcinoma. Lancet 362, 1907-1917. <https://doi.org/10.1016/S0140-6736(03)14964-1>
19. Lutterbach, B., Zeng, Q., Davis, L. J., Hatch, H., Hang, G., Kohl, N. E., Gibbs, J. B., Pan, B. S. (2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67, 2081-2088. <https://doi.org/10.1158/0008-5472.CAN-06-3495>
20. Margolskee, E., Bao, F., de Gonzalez, A. K., Moreira, R. K., Lagana, S., Sireci, A. N., Sepulveda, A. R., Remotti, H., Lefkowitch, J. H., Salomao, M. (2016) Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. Diagn. Pathol. 11, 27. <https://doi.org/10.1186/s13000-016-0475-5>
21. Monga, S. P., Monga, H. K., Tan, X., Mule, K., Pediaditakis, P., Michalopoulos, G. K. (2003) β-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 124, 202-216. <https://doi.org/10.1053/gast.2003.50000>
22. Monga, S. P. (2006) Hepatic adenomas: presumed innocent until proven to be β-catenin mutated. Hepatology 43, 401-404. <https://doi.org/10.1002/hep.21110>
23. Moran-Jones, K. (2016) The therapeutic potential of targeting the HGF/cMET axis in ovarian cancer. Mol. Diagn. Ther. 20, 199-212. <https://doi.org/10.1007/s40291-016-0201-8>
24. Nakamoto, Y. (2016) Promising new strategies for hepatocellular carcinoma. Hepatol. Res. 47, 251-265. <https://doi.org/10.1111/hepr.12795>
25. Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., Comoglio, P. M. (2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361. <https://doi.org/10.1016/S1535-6108(03)00085-0>
26. Pievsky, D., Pyrsopoulos, N. (2016) Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date. J. Hepatocell. Carcinoma 3, 69-76. <https://doi.org/10.2147/JHC.S106072>
27. Rebouissou, S., Imbeaud, S., Balabaud, C., Boulanger, V., Bertrand-Michel, J., Terce, F., Auffray, C., Bioulac-Sage, P., Zucman-Rossi, J. (2007) HNF1α inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response elementbinding protein (ChREBP) activation. J. Biol. Chem. 282, 14437-14446. <https://doi.org/10.1074/jbc.M610725200>
28. Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P., Zucman-Rossi, J. (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204. <https://doi.org/10.1038/nature07475>
29. Reznik, Y., Dao, T., Coutant, R., Chiche, L., Jeannot, E., Clauin, S., Rousselot, P., Fabre, M., Oberti, F., Fatome, A., Zucman-Rossi, J., Bellanne-Chantelot, C. (2004) Hepatocyte nuclear factor-1α gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J. Clin. Endocrinol. Metab. 89, 1476-1480. <https://doi.org/10.1210/jc.2003-031552>
30. Santoro, A., Simonelli, M., Rodriguez-Lope, C., Zucali, P., Camacho, L. H., Granito, A., Senzer, N., Rimassa, L., Abbadessa, G., Schwartz, B., Lamar, M., Savage, R. E., Bruix, J. (2013) A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br. J. Cancer 108, 21-24. <https://doi.org/10.1038/bjc.2012.556>
31. Schlageter, M., Terracciano, L. M., D’Angelo, S., Sorrentino, P. (2014) Histopathology of hepatocellular carcinoma. World J. Gastroenterol. 20, 15955-15964. <https://doi.org/10.3748/wjg.v20.i43.15955>
32. Spannbauer, M. M., Trautwein, C. (2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. Hepatology 49, 1387-1389. <https://doi.org/10.1002/hep.22902>
33. Suzuki, K., Hayashi, N., Yamada, Y., Toshihara, H., Miyamoto, Y., Ito, Y., Ito, T., Katayama, K., Sasaki, Y., Ito, A., Kisida, Y., Kashiwagi, T., Fusamoto, H., Kamada, T. (1994) Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 20, 1231-6. <https://doi.org/10.1002/hep.1840200520>
34. Takashima, K., Ito, Y., Gonzalez, F. J., Nakajima, T. (2008) Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Pparα-null mice. J. Occup. Health 50, 169-180. <https://doi.org/10.1539/joh.L7105>
35. Takayama, H., LaRochelle, W. J., Sharp, R., Otsuka, T., Kriebel, P., Anver, M., Aaronson, S. A., Merlino, G. (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. USA 94, 701-706. <https://doi.org/10.1073/pnas.94.2.701>
36. Takeo, S., Arai, H., Kusano, N., Harada, T., Furuya, T., Kawauchi, S., Oga, A., Hirano, T., Yoshida, T., Okita, K., Sasaki, K. (2001) Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet. Cytogenet. 130, 127-132. <https://doi.org/10.1016/S0165-4608(01)00479-4>
37. Tanaka, S., Arii, S. (2012) Molecular targeted therapies in hepatocellular carcinoma. Semin. Oncol. 39, 486-492. <https://doi.org/10.1053/j.seminoncol.2012.05.005>
38. Tavian, D., De Petro, G., Benetti, A., Portolani, N., Giulini, S. M., Barlati, S. (2000) u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer 87, 644-649. <https://doi.org/10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.0.CO;2-W>
39. Trojan, J., Zeuzem, S. (2013) Tivantinib in hepatocellular carcinoma. Expert Opin. Investig. Drugs 22, 141-147. <https://doi.org/10.1517/13543784.2013.741586>
40. Trovato, M., Vitarelli, E., Grosso, M., Alesci, S., Benvenga, S., Trimarchi, F., Barresi, G. (2004) Immunohistochemical expression of HGF, c-MET and transcription factor STAT3 in colorectal tumors. Eur. J. Histochem. 48, 291-297.
41. Van der Borght, S., Libbrecht, L., Katoonizadeh, A., Aerts, R., Nevens, F., Verslype, C., Roskams, T. A. (2007) Nuclear β-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 51, 855-856. <https://doi.org/10.1111/j.1365-2559.2007.02862.x>
42. Van Der Steen, N., Deben, C., Deschoolmeester, V., Wouters, A., Lardon, F., Rolfo, C., Germonpre, P., Giovannetti, E., Peters, G. J., Pauwels, P. (2016) Better to be alone than in bad company: the antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World J. Clin. Oncol. 7, 425-432. <https://doi.org/10.5306/wjco.v7.i6.425>
43. Wang, K., Lim, H. Y., Shi, S., Lee, J., Deng, S., Xie, T., Zhu, Z., Wang, Y., Pocalyko, D., Yang, W. J., Rejto, P. A., Mao, M., Park, C. K., Xu, J. (2013) Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 58, 706-717. <https://doi.org/10.1002/hep.26402>
44. Yong, X., Tang, B., Xiao, Y. F., Xie, R., Qin, Y., Luo, G., Hu, C. J., Dong, H., Yang, S. M. (2016) Helicobacter pylori upregulates Nanog and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer. Cancer Lett. 374, 292-303. <https://doi.org/10.1016/j.canlet.2016.02.032>
45. Zucman-Rossi, J., Jeannot, E., Nhieu, J. T., Scoazec, J. Y., Guettier, C., Rebouissou, S., Bacq, Y., Leteurtre, E., Paradis, V., Michalak, S., Wendum, D., Chiche, L., Fabre, M., Mellottee, L., Laurent, C., Partensky, C., Castaing, D., Zafrani, E. S., Laurent-Puig, P., Balabaud, C., Bioulac-Sage, P. (2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43, 515-524. <https://doi.org/10.1002/hep.21068>
46. Zucman-Rossi, J. (2008) Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations. J. Hepatol. 48, 884-886. <https://doi.org/10.1016/j.jhep.2008.02.001>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive